Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, Shune L, Isufi I, Harrison SJ, Shah UA, Schecter JM, Vogel M, Lendvai N, Gries KS, Katz EG, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho OC, Patel N, Florendo E, Karlin L, Weisel K. Mina R, et al. Among authors: shah ua. Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X. Lancet Haematol. 2025. PMID: 39756844 Clinical Trial.
Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.
Kaj-Carbaidwala B, Fevery J, Adler DG, Bergquist A, de Ridder L, Deneau M, Gower-Rousseau C, Chapman RW, Lynch KD, Stedman CAM, Wilson DC, Shah U, Goyal L, Winter HS, Lennerz JK. Kaj-Carbaidwala B, et al. Among authors: shah u. J Pediatr Gastroenterol Nutr. 2024 Dec 20. doi: 10.1002/jpn3.12443. Online ahead of print. J Pediatr Gastroenterol Nutr. 2024. PMID: 39704261
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivière I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Jurgens EM, et al. Among authors: shah ua. J Clin Oncol. 2024 Dec 4:JCO2401785. doi: 10.1200/JCO-24-01785. Online ahead of print. J Clin Oncol. 2024. PMID: 39631041
Searching for Asymmetric and Heavily Precessing Binary Black Holes in the Gravitational Wave Data from the LIGO Third Observing Run.
Schmidt S, Caudill S, Creighton JDE, Tsukada L, Doke A, Jain M, Ray A, Adhicary S, Baral P, Baylor A, Cannon K, Cousins B, Ewing B, Fong H, George RN, Godwin P, Hanna C, Harada R, Huang YJ, Huxford R, Joshi P, Kennington J, Kuwahara S, Li AKY, Magee R, Meacher D, Messick C, Morisaki S, Mukherjee D, Niu W, Pace A, Posnansky C, Sachdev S, Sakon S, Singh D, Shah U, Tapia R, Tsutsui T, Ueno K, Viets A, Wade L, Wade M. Schmidt S, et al. Among authors: shah u. Phys Rev Lett. 2024 Nov 15;133(20):201401. doi: 10.1103/PhysRevLett.133.201401. Phys Rev Lett. 2024. PMID: 39626704
Efficacy and Safety of Biosimilar Ranibizumab (OPTIMAB®) versus Innovator Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration: A Double-Blind, Randomized, Multicenter, Phase III Study.
Rana PJ, Deshmukh H, Shah U, Kumar V, Kanungo S, Singhal D, Mahapatra SK, Vakharia I, Jaiswal M, Gondane A, Vaidya P, Shahavi V, Shandilya H, Pawar D, Sharma A. Rana PJ, et al. Among authors: shah u. Clin Ophthalmol. 2024 Oct 29;18:3071-3081. doi: 10.2147/OPTH.S488866. eCollection 2024. Clin Ophthalmol. 2024. PMID: 39493839 Free PMC article. Clinical Trial.
751 results